Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: back pain

FDA Approves Belimumab & Voclosporin for Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  March 24, 2021

In December, the FDA approved belimumab, the first drug approved to treat lupus nephritis, an historic action that was rapidly followed in January by the approval of a second treatment for lupus nephritis, voclosporin.

Filed under:ConditionsDrug UpdatesSystemic Lupus Erythematosus Tagged with:belimumabFDAFDA approvalLupus nephritisU.S. Food and Drug Administration (FDA)voclosporin

Louisa Ziglar, MD, FACR: ‘Everyone Can Be an Advocate’

Leslie Mertz, PhD  |  March 18, 2021

When it comes to advocating for rheumatology, it’s never too early or late in your career to begin, and no effort is too small to have an impact, says Dr. Ziglar, a private practitioner and member of the Government Affairs Committee.

Filed under:Legislation & AdvocacyProfiles Tagged with:AdvocacyGovernment Affairs Committee (GAC)Louisa Ziglar

Clinicians Should Recommend Exercise More Often, Expert Says

Thomas R. Collins  |  March 15, 2021

ACR CONVERGENCE 2020—Research has shown time and again the benefits and low risk of physical activity for people with rheumatic diseases, but only a third or less of patients meet guidelines for this activity, Patricia Katz, PhD, professor of medicine and health policy at the University of California, San Francisco, said in the ARP Distinguished…

Filed under:Conditions Tagged with:ACR Convergence 2020fatiguePain Management

Experts Discuss 3 Frequently Overlooked Syndromes

Thomas R. Collins  |  March 15, 2021

ACR CONVERGENCE 2020—Myalgic encephalomyelitis/chronic fatigue syndrome, postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome were the topics of the day in the ever-popular Curbside Consults session in November 2020. POTS An anxious woman with a chronic headache and constant myofascial pain in the neck and upper back, assorted gastrointestinal symptoms, chronic severe fatigue,…

Filed under:Conditions Tagged with:ACR Convergence 2020mast cell activation syndrome (MCAS)myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS)postural orthostatic tachycardia syndrome (POTS)

Upadacitnib for RA: Researchers Compared Upadacitinib with Placebo & Adalimumab in Patients with RA & an Inadequate Response to Methotrexate

Vanessa Caceres  |  March 9, 2021

In phase 3 clinical trial, upadacitnib proved superior to placebo and adalimumab in improving the signs and symptoms of RA in patients on stable background methotrexate.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020ACR Convergence 2020 – RAadalimumabjakinibupadacitinib

Diet, Microbes & Inflammation: Unique Microbial Genetic Strains in Inflammatory Disease, Plus a Possible Arthritis Diet

Susan Bernstein  |  March 4, 2021

Experts at ACR Convergence 2020 addressed how diet & the body’s microbiome affect chronic diseases.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2020Dietgut microbiotainflammationMicrobiome

Myositis & the Heart: New Perspectives on the Pathogenesis & Management of Cardiac Involvement in Myositis

Carina Stanton  |  February 18, 2021

Experts discuss the diagnosis and treatment of myositis-related cardiovascular disease.

Filed under:ACR ConvergenceConditionsMeeting ReportsMyositis Tagged with:ACR Convergence 2020cardiovascularheartHeart Diseasemyocarditismyositis

Updated Clinical Practice Guidelines for Lyme Disease, Lyme Arthritis

Elizabeth Hofheinz, MPH, MEd  |  February 16, 2021

A team of healthcare practitioners and researchers, spearheaded by the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN) and the ACR, has developed updated evidence-based clinical practice guidelines for the prevention, diagnosis and treatment of Lyme disease. The 2020 guidelines cover a wide variety of Lyme disease manifestations, including Lyme arthritis. Linda…

Filed under:Conditions Tagged with:GuidelinesLyme arthritisLyme Disease

European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP  |  February 4, 2021

In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Ankylosing SpondylitisEuropean UnionPsoriatic Arthritisupadacitinib

Reproductive Health, Beyond the Guidelines: Rheumatologists Must Think About Patients’ Psychosocial Needs

Mary Beth Nierengarten  |  January 25, 2021

Experts discuss how rheumatologists must consider the psychosocial aspect of care in the decision-making process for women when addressing their reproductive health needs, in addition to medication safety.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2020Association of Rheumatology Professionals (ARP)biopsychosocialpatient carepregnancypsychosocial

  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 162
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences